Floatz logo

Palonosetron

Breast Cancer Patients Treated With T-DXd

Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Breast Cancer Patients Treated With T-DXd cohort.

Asset / SponsorPhaseRating
Netupitant
Tianjin Medical University Cancer Institute and Hospital
Phase 4BBB
MEGESTROL ACETATE IMPURITY B
Tianjin Medical University Cancer Institute and Hospital
Phase 4BB

Same molecule, other indications

Palonosetron is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
Nausea and VomitingDormant
BB
Indicative ·
70 / 100
View asset →
cancer of unknown primary siteDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →